Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

Abstract: Methods and systems for anomaly detection include encoding a multivariate time series and a multi-type event sequence using respective transformers and an aggregation network to generate a feature vector. Anomaly detection is performed using the feature vector to identify an anomaly within a system. A corrective action is performed responsive to the anomaly to correct or mitigate an effect of the anomaly. The detected anomaly can be used in a healthcare context to support decision making by medical professionals with respect to the treatment of a patient. The encoding may include machine learning models to implement the transformers and the aggregation network using deep learning.

Abstract: Active antenna units and/or base station antennas are provided that include a reflector body with heat dissipation structures that can be directly exposed to environmental conditions during use. The heat dissipation structures have frequency selective surfaces and can be formed of sheet metal or provided as separate extruded or die cast members that can be coupled to the reflector body.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: Methods and systems for training a model include distinguishing hidden states of a monitored system based on condition information. An encoder and decoder are generated for each respective hidden state using forward and backward autoencoder losses. A hybrid hidden state is determined for an input sequence based on the hidden states. The input sequence is reconstructed using the encoders and decoders and the hybrid hidden state. Parameters of the encoders and decoders are updated based on a reconstruction loss.

Abstract: A computer-implemented method for simulating vehicle data and improving driving scenario detection is provided.

Abstract: A multi-modal pre-training model acquisition method, an electronic device and a storage medium, which relate to the fields of deep learning and natural language processing, are disclosed. The method may include: determining, for each image-text pair as training data, to-be-processed fine-grained semantic word in the text; masking the to-be-processed fine-grained semantic words; and training the multi-modal pre-training model using the training data with the fine-grained semantic words masked.

Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting kinase activity, and for treating cancer.

Abstract: The fuel cell control system includes: a reactor; an air compressor, wherein the air compressor has a compressing cavity, the compressing cavity has a gas inlet and a gas outlet, a rotatable pressure wheel is disposed inside the compressing cavity, and the gas outlet is in communication with the reactor; a control flow channel, wherein a first end of the control flow channel is in communication with the gas-intake side of the pressure wheel, a second end of the control flow channel is in communication with the wheel-back side of the pressure wheel, and the control flow channel is provided with a return valve for regulating the flow rate of the control flow channel; and a central control unit, wherein the central control unit is communicatively connected to the return valve to control the opening degree of the return valve.

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol “APLNR”). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: The present invention relates to the technical field of biology, and provides a quantitative detection method for six antibiotic drug resistant genes in an aquatic product. The method comprises: taking the total DNA of bacteria carried by an aquatic product to be tested as a template, respectively using a primer pair I to a primer pair VI to carry out fluorescent quantitative PCR amplification, and quantifying antibiotic drug resistant genes tetA, sul2, cmlA, qnrS, aac(6?)-Ib, and blaPSE in said aquatic product according to the Ct value.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting kinase activity, and for treating cancer.

Abstract: The air compressor includes: a housing assembly, wherein the housing assembly has a first installation cavity, a second installation cavity and a rotation-shaft cooperating cavity, and the first installation cavity has a gas inlet and a gas outlet; a rotor shaft, wherein the rotor shaft is rotatably fitted inside the rotation-shaft cooperating cavity, and extends into the first installation cavity and the second installation cavity; a pressure wheel, wherein the pressure wheel is nested to the rotor shaft and is located inside the first installation cavity, and the housing assembly is provided with a controlling flow channel for communicating the gas-intake side and the wheel-back side of the pressure wheel; and a driving assembly, wherein the driving assembly is nested to the rotor shaft and is located inside the second installation cavity.

Abstract: The fuel cell control system includes: a reactor; an air compressor, wherein the air compressor has a compressing cavity, the compressing cavity has a gas inlet and a gas outlet, a rotatable pressure wheel is disposed inside the compressing cavity, and the gas outlet is in communication with the reactor; a control flow channel, wherein a first end of the control flow channel is in communication with the gas-intake side of the pressure wheel, a second end of the control flow channel is in communication with the wheel-back side of the pressure wheel, and the control flow channel is provided with a return valve for regulating the flow rate of the control flow channel; and a central control unit, wherein the central control unit is communicatively connected to the return valve to control the opening degree of the return valve.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor, gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.